Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7290324 | 0.98 | HRH3 (0.42) | CARM1PRMT6PRMT8HRH3ALDH1A1 | |
| SCHEMBL20332097 | 0.86 | HRH3 (0.46) | CARM1PRMT6PRMT8HRH3ALDH1A1 | |
| SCHEMBL9915070 | 0.85 | HRH3 (0.50) | CARM1PRMT6PRMT8HRH3ALDH1A1 | |
| SCHEMBL21348734 | 0.85 | HRH3 (0.50) | HRH3MAPTKDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL18911024 | 0.84 | SIGMAR1 (0.35) | ALDH1A1KDM4E | |
| SCHEMBL19185679 | 0.84 | CARM1 (0.38) | CARM1PRMT6PRMT8HRH3ALDH1A1 | |
| SCHEMBL18708827 | 0.84 | SIGMAR1 (0.33) | ALDH1A1KDM4E | |
| SCHEMBL10226064 | 0.83 | HRH3 (0.54) | HRH3ALDH1A1MAPTKDM4EL3MBTL1 | |
| SCHEMBL15363087 | 0.82 | HRH3 (0.41) | CARM1PRMT6PRMT8HRH3ALDH1A1 | |
| SCHEMBL13089689 | 0.82 | HRH3 (0.41) | HRH3ALDH1A1MAPTKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-3753939-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-9717713-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2096924-B1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | UNIV CHINA MEDICAL (TW) | 2013-02-13 | — | — | EP | disclosed |
| EP-2468747-A1 | 2-Selenophene-4-quinolones as anticancer agents | China Medical University (TW) | 2012-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | CARM1 1653/4885PRMT6 678/4885PRMT8 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.